Andreas Weiss

Company: Norvartis

Job title: Associate Director, Oncology Drug Discovery

Seminars:

Panel Discussion: Does Pan-RAS Hold the Future of Precision Medicine? Exploring Combination Potential & Targeting Novel Isoforms 9:30 am

• What is the scope for pan-RAS beyond canonical RAS isoforms? • What is the scope for targeting patient populations with NRAS isoforms? Can go as far as drugging melanoma? • What combination therapies should be deployed with pan-RAS and how can we inform this? Read more

day: Day One